Literature DB >> 2996562

In vitro and in vivo inhibitory effects of propentofylline on cyclic AMP phosphodiesterase activity.

K Nagata, T Ogawa, M Omosu, K Fujimoto, S Hayashi.   

Abstract

1-(5'-Oxohexyl)-3-methyl-7-propylxanthine (propentofylline), a vasoactive agent, was investigated for its in vitro and in vivo inhibitory effects on cyclic AMP phosphodiesterases activity. Soluble cyclic AMP phosphodiesterases from the cerebral cortex, heart muscle, descending aorta and platelet showed two Km values, high and low. The low Km values were in the range of 2.1-3.0 mumol/l and the high Km values were 111, 28.7, 30.2 and 18.7 mumol/l, respectively. Propentofylline inhibited the enzyme from the 4 tissues noncompetitively. Ki values for the low and high Km cyclic AMP phosphodiesterases were 83.4-135 and 107-188 mumol/l, respectively. In the four tissues, the enzyme inhibitory effect of propentofylline was 1/4 to 1/10 times that of 3-isobutyl-1-methylxanthine (IBMX) but 3-9 and 6-17 times as potent as those of theophylline and caffeine, respectively. The in vivo cyclic AMP phosphodiesterase inhibitory effect of propentofylline was determined in mice using an elevation of plasma cyclic AMP levels as a measure. When given both singly and in combination with isoprenaline (isoproterenol), propentofylline was a potent inhibitor of cyclic AMP phosphodiesterase in the case of intravenous administration.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2996562

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  7 in total

Review 1.  Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia.

Authors:  C D Nicholson
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  Systemic administration of propentofylline, ibudilast, and (+)-naltrexone each reverses mechanical allodynia in a novel rat model of central neuropathic pain.

Authors:  Amanda Ellis; Julie Wieseler; Jacob Favret; Kirk W Johnson; Kenner C Rice; Steven F Maier; Scott Falci; Linda R Watkins
Journal:  J Pain       Date:  2014-01-09       Impact factor: 5.820

3.  Effect of propentofylline (HWA 285) on extracellular purines and excitatory amino acids in CA1 of rat hippocampus during transient ischaemia.

Authors:  P Andiné; K A Rudolphi; B B Fredholm; H Hagberg
Journal:  Br J Pharmacol       Date:  1990-08       Impact factor: 8.739

4.  Propentofylline decreases tumor growth in a rodent model of glioblastoma multiforme by a direct mechanism on microglia.

Authors:  Valerie L Jacobs; Russell P Landry; Yingna Liu; Edgar Alfonso Romero-Sandoval; Joyce A De Leo
Journal:  Neuro Oncol       Date:  2011-11-15       Impact factor: 12.300

5.  Propentofylline-induced astrocyte modulation leads to alterations in glial glutamate promoter activation following spinal nerve transection.

Authors:  V L Tawfik; M R Regan; C Haenggeli; M L Lacroix-Fralish; N Nutile-McMenemy; N Perez; J D Rothstein; J A DeLeo
Journal:  Neuroscience       Date:  2008-02-15       Impact factor: 3.590

Review 6.  Neuroimmune interactions and pain: focus on glial-modulating targets.

Authors:  Edgar Alfonso Romero-Sandoval; Ryan J Horvath; Joyce A DeLeo
Journal:  Curr Opin Investig Drugs       Date:  2008-07

7.  Propentofylline targets TROY, a novel microglial signaling pathway.

Authors:  Valerie L Jacobs; Yingna Liu; Joyce A De Leo
Journal:  PLoS One       Date:  2012-05-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.